Enalapril Maleate Tablets, USP, 5 mg, 100 Tablets (10 x 10) Unit Dose per carton, Rx only, Manufa...
FDA Drug Recall #D-0980-2018 — Class III — June 26, 2018
Recall Summary
| Recall Number | D-0980-2018 |
| Classification | Class III — Low risk |
| Date Initiated | June 26, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | MAJOR PHARMACEUTICALS |
| Location | Livonia, MI |
| Product Type | Drugs |
| Quantity | 5,933 cartons |
Product Description
Enalapril Maleate Tablets, USP, 5 mg, 100 Tablets (10 x 10) Unit Dose per carton, Rx only, Manufactured by: Wockhardt Limited, H-14/2, M.I.D.C. Area, Waluj, Aurangabad, Maharashtra, India; Distributed by: Wockhardt USA LLC., 20 Waterview Blvd., Parsippany, NJ 07054; Distributed by: MAJOR Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152; NDC 0904-5502-61.
Reason for Recall
Failed Impurities/Degradation Specifications: Sub-recall because this repackaged product was recalled by the manufacturing firm, Wockhardt, due to out-of-specification results for the Enalapril DiKetopiperazine degradation product.
Distribution Pattern
Nationwide in the USA and Puerto Rico.
Lot / Code Information
Lot #: T-01082, Exp 08/18; DR10445A, Exp 09/18; DR10443A, Exp 12/18; DR10445B, Exp 03/19; DR10725A, Exp 07/19; DS10024A, DS10040A, Exp 10/19.
Other Recalls from MAJOR PHARMACEUTICALS
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1583-2019 | Class II | DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS, USP... | Apr 24, 2019 |
| D-1466-2019 | Class II | Losartan Potassium Tablets, USP. 50 mg. NDC# 09... | Jan 10, 2019 |
| D-1026-2018 | Class II | Doxycycline Hyclate Tablets, USP, 100 mg, Rx On... | Jul 30, 2018 |
| D-0966-2018 | Class II | Unit Dose Valsartan Tablets, USP, 80 mg. Rx onl... | Jul 18, 2018 |
| D-0967-2018 | Class II | Unit Dose Valsartan Tablets, USP. 160 mg. Rx on... | Jul 18, 2018 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.